当前位置: 首页 > 期刊 > 《中国健康月刊》 > 2010年第7期 > 正文
编号:12294499
雷米普利与依那普利对于高血压患者预后的临床比较(2)
http://www.100md.com 2010年7月1日 雷 文 陈 君
第1页

    参见附件。

     2. Cowan BR, Young AA, Anderson C. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]) [J]. Am J Cardiol, 2009, 104(11): 1484-1489.

    3. Verdecchia P, Sleight P, Mancia G. Effects of telmisartan, ramipril, and their combination on the left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease[J]. Circulation, 2009, 120(14): 1380-1389.

    4. Mann JF, Schmieder RE, McQueenM, et al. Renal outcomes with telmisartan, ramip ril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial [J]. Lancet, 2008, 372 (9638): 547-553.

    5. Yilmaz MI, Saglam M, Sonmez A. Improving proteinuria, endothelial fuctions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan[J]. Blood Purif, 2007, 25(4): 327-335.

    6. 王瑞,闫自强,王昕欣,杨卫红。长期口服雷米普利对老年慢性心力衰竭的影响[J]。心脏杂志,2008, 20(3):372.

    7. Sweileh WM, Sawalha AF, Rinno TM, et al. Optimal dosing of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: a cross-sectional study in Palestine [J]. Ann SaudiMed, 2009, 29 (2): 119-122.

    8. Yip GW, Wang M, Wang T.The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction [J]. Heart, 2008, 94(5): 573-580.

    (责任审校:孟有全)

您现在查看是摘要介绍页,详见PDF附件(1277kb)